🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors

First clinical data beyond lung cancer for the B7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig!

📊 N=139 efficacy-evaluable: uORR 48.9% | cORR 39.6% | DCR 87.8%

👀 Melanoma (n=26): uORR 30.8% | cORR 26.9% | DCR 80.8%

Activity was broadly maintained despite prior IO and/or bevacizumab exposure.

Safety appeared manageable, with mainly G1–2 GI/hematologic TRAEs, no DLTs or treatment-related deaths, and 2 investigator-reported ILD cases 👍🏼

@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma